



Setting New Standards in Neuroscience

Ronald E. Sussek, Ph.D.
Vice President, Corporate Business Development
Direct Tel: 714/753-6132 Fax: 714/753-6161
Email: rsusck@cocensys.com

FILE COPY

Copied to RHH, Craig,
Al, Andrej + Dennis

201 Technology Drive
Irvine, CA 92618

Tel: (714) 753-6100
Fax: (714) 753-6161
Fax: (714) 753-6194

Via facsimile: 908-739-0713

January 16, 1998

Robert H. Harris, Ph.D.
FEDERAL RESEARCH CONSULTANTS
A Division of Harris FRC Corporation
2139 Route 35
Holmdel, NJ 07733

Re: ADD 234037

Dear Dr. Harris:

Thank you for the confidential material describing your anticonvulsant and anti-ischemic compound, ADD 234037, and for your follow-up telephone call earlier this week.

I have reviewed the technical package with my scientific staff. Even though the compound's oral bioavailability and apparent good therapeutic index may be advantages over other compounds in development, we have determined that ADD 234037 is not a compound we wish to pursue due to its relative weak potency in both *in vivo* and *in vitro* assays.

Thank you for the opportunity to evaluate ADD 234037. I look forward to another chance to work with Federal Research Consultants on other projects in the future.

Sincerely,

Ronald E. Sussek
Vice President, Corporate Business Development

dlg:RES\letters\FRC011698.doc